艾普拉唑肠溶片用于治疗反流性食管炎的有效性及安全性Meta分析

Meta-analysis of the efficacy and safety of Ilaprazole Enteric-Coated Tablets on reflux esophagitis

目的系统评估艾普拉唑肠溶片治疗反流性食管炎的有效性和安全性。方法检索CNKI、VIP、万方数据知识服务平台及PubMed、Web of Science、EMBase、The Cochrane Library数据库,搜集2021年4月之前公开发表的应用艾普拉唑肠溶片治疗RE的随机对照试验(RCT)。纳入符合标准的文献,经数据提取和质量评价后,采用RevMan 5.4软件对内镜下有效率、症状缓解率和不良反应发生率进行统计分析。结果共纳入9个RCT,包括1115名RE患者。Meta分析结果显示,有效性方面,10 mg艾普拉唑肠溶片与40 mg艾司奥美拉唑肠溶片相比,内镜下有效率(90.08%vs.90.00%,P>0.05)和症状缓解率(91.79%vs.91.23%,P>0.05)相当;安全性方面,艾普拉唑肠溶片与艾司奥美拉唑肠溶片相比,不良反应发生率较低(7.99%vs.8.66%,P>0.05),但差异无统计学意义。结论艾普拉唑肠溶片应用更少的剂量能达到与艾司奥美拉唑肠溶片相似的治疗效果,能有效治疗RE且安全性良好。

Objective To evaluate the efficacy and safety of Ilaprazole Enteric-Coated Tablets in the treatment of RE.Methods The databases of CNKI,VIP,Wanfang Data,PubMed,Embase,and The Cochrane Library were searched to collect all the randomized controlled trials(RCTs)of Ilaprazole in the treatment of RE published before April 2021.After data extraction and quality evaluation,the RCTs meeting the inclusion criteria were performed,and the meta-analysis was conducted by RevMan 5.4.Results Nine RCTs were included,with a total of 1115 patients of RE.The results of the meta-analysis showed that Ilaprazole Enteric-Coated Tablets were comparable to Esomeprazole Enteric-Coated Tablets in both endoscopic efficiency(90.08%vs.90.00%,P>0.05)and symptom relief rates(91.79%vs.91.23%,P>0.05),and there was no statistically significant difference in the incidence of adverse reactions(7.99%vs.8.66%,P>0.05).Conclusion Ilaprazole Enteric-Coated Tablets with lower doses were comparable to Esomeprazole Enteric-Coated Tablets which showed good efficacy and safety in the treatment of reflux esophagitis.